| pubmed-article:9352450 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9352450 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9352450 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:9352450 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9352450 | lifeskim:mentions | umls-concept:C0026896 | lld:lifeskim |
| pubmed-article:9352450 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:9352450 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
| pubmed-article:9352450 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:9352450 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:9352450 | pubmed:dateCreated | 1997-12-18 | lld:pubmed |
| pubmed-article:9352450 | pubmed:abstractText | We evaluated cyclosporine A (CsA) treatment in 9 patients (6 female and 3 male), 16-63 years old, with severe myasthenia gravis (MG) for a mean period of 2 years (range 16-36 months). All of the patients had been previously treated either with corticosteroids or by combined immunotherapy, and 5 needed periodic plasma exchanges. The reduction of plasmapheresis cycles in the 5 patients who needed periodic plasma exchange to maintain an acceptable quality of life showed an impressive cost-benefit analysis. During CsA treatment 7 of 9 patients improved their muscle strength and functional score. In all the patients except one the corticosteroid dosage was reduced and in 7 of the 9 patients the dose reduction was over 50% with subsequent reduction of the corticosteroid side effects. The findings showed that initiation of CsA treatment increased muscle strength and reduced corticosteroid dosage. The most common CsA side effects were: a serum creatinine increase that occurred in the first 6-12 months of therapy in 8 patients, other side effects like hypertrichosis and gingival hyperplasia were present in four patients. Blood pressure increase was found in only one patient. CsA treatment may be a valuable and cost effective treatment in severe MG. | lld:pubmed |
| pubmed-article:9352450 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9352450 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352450 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9352450 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352450 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352450 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9352450 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9352450 | pubmed:issn | 0340-5354 | lld:pubmed |
| pubmed-article:9352450 | pubmed:author | pubmed-author:AngeliniCC | lld:pubmed |
| pubmed-article:9352450 | pubmed:author | pubmed-author:BonifatiD MDM | lld:pubmed |
| pubmed-article:9352450 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9352450 | pubmed:volume | 244 | lld:pubmed |
| pubmed-article:9352450 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9352450 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9352450 | pubmed:pagination | 542-7 | lld:pubmed |
| pubmed-article:9352450 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:meshHeading | pubmed-meshheading:9352450-... | lld:pubmed |
| pubmed-article:9352450 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9352450 | pubmed:articleTitle | Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. | lld:pubmed |
| pubmed-article:9352450 | pubmed:affiliation | Department of Neurological and Psychiatric Sciences, University of Padova, Padua, Italy. | lld:pubmed |
| pubmed-article:9352450 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9352450 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9352450 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:9352450 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9352450 | lld:pubmed |
